moving on. >> who is going to make more money, biogen or neuman? >> biogen. lot more, yeah. >> fine. >> biogen will make a lot more money. >> all right >> let's move on we have some really interesting guests >> okay. >> who have snuck on while i'm looking for my notes we have a busy morning at post nine hans vestberg, and kevin mayor joins us as well >> how did you get these guys? >> you pick up the phone and good things happen. >> i said i think i know those guys can we get them? they're right here >> thanks for being here today you got some news, we're going to break it right now in terms of disney plus, which kevin you oversee at disney. november 12th the rollout date a lot of people may have already seen the advertisements. and hans, as well, you were partnering with them to provide your wireless customers, your unlimited, your fios customers as well with disney plus tell us about the deal. >> we are, of course, extremely excited to partner with disney we offer to our customers basically exclusive with disney plus, we'll bring that one year for free and,

the news sent smars of biogen 26%, the best one-day gain since 1996. but as meg tyrell reports while there is hope there is a long road ahead. >> it was a diagnosis you don't expect in the early0s. jeff was only 51 when he was told he has early on set alzhmer'ss disease with no drugs approved to slow alzheimer's's progression he enrolled in a clinical trial of an experimental drug made by biogen designed to attack the am many oid planting build up in the brain kwh he you participate in the clinical trial or the experience for me participating in the clinical trial troo was one of add las vegas i was happy to to be part of it. >> he was in the trial three years going every month to a center of to have the infusion. he says he thought it was representing. >> everyone in my family noticed a marked improvement in my dsh my cognition. for your family to see you doing things that you were having trouble with before, you know, those are things that become very exciting to you. >> then in march of this year, shocking news. biogen stopped development of the dru

bows biogen the best day in 20 years. what's behind the surge and what it means for the drug giant.for the drug giant. fms returns stay with us's boun, because you're better off healthy. ...owning and running the biggesta small business is finding the right people. in hiring our first recruiter, we decided to post a job on linkedin. they had to have worked... ...at a recruiter firm and be bilingual. when we saw ana maria's profile... ...she had a ton of experience in hr. the interview went really well. and she seemed like someone who could really sell mckenzie to perspective employees. we found the best person to find the best person for us. post a job today at linkedin.com/grow >>> well bang toplace fms. following a major develop story out of boeing. a new head of the commercial airplanes tuition. let's get to phil lebeau with the details. >> we've said sometime pressure has been building on the beardship and the boeing board of directors to show it's taking actions in terms of making changes that will send a message that the company is determined to get the 737 max resolved and ba

>>> biotech getting a bounce in the back of biogen two names you need to watch in the space. "halftime report" starts right now. >>> welcome. good to have you with us our investment committee today, joe, stephanie, josh, brynn is back let's begin with this big day for earnings stefrl dow stocks are moving this hour. let's talk about some of those right there. stephanie link, you go first mcdonald's is a drag comps below. they had the first eps miss in two years. oh, my goodness, your sale completely out of this company earlier or later last week, whenever it was, looks good today. >> i actually thought it was going to be worse than what they put up today a 5.9 global comp is impressive but the problem is they have to investment invest substantially to keep up with the competition. while i liked the story a while ago because of the digital initiatives and the ceo and all the things he has been doing they have to spend you don't get the operating leverage positively i was looking for. i got lucky, but i think it's a great company and if it weakens further i might get back in. >

another in japan is a partner with biogen.s of companies looking at the disease, at this area. it also gives hope for the whole sector, but as we said, we remain cautiously optimistic, or still renderin w. -- or still wondering. we want to see more of this data. ofaine: that is sam fazeli bloomberg intelligence. guy: after years of drama, we will have a new ceo to talk about the future of the sports apparel maker under armour. that's coming up. this is bloomberg. ♪ ♪ live from new york, i'm romaine bostick. guy: from london, i'm guy johnson. this is "bloomberg markets." romaine: time for our stock of the hour, mcdonald's, one of the biggest underperformers in the s&p 500, dropping more than 3% after it released third-quarter results. kailey leinz is here with more. it's been one of the out performers over the last year, so what happened? kailey: the stock has done markedly well -- has done remarkably well. it had a blowout second-quarter, and we have kind of seen things pulled down, especially with comp sales. scale, actually

how about the biogen how about the centene or bristol-myers. look at today's winners.asboro took a tumble. wasn't it nasty. i sit down with the ceo. he comes on even if it's a bad day. is beyond meat as great as it is and tasty as it is a little too much like gopro and lodge gitec have the ceo so stay with cramer >> announcer: don't miss a second of "mad money." follow @jimcramer on twitter have a question, tweet cramer, #madtweets send jim an email to madmoney@cnbc.com or give us a call at 1-800-743-cnbc miss something, head to madmoney.cnbc.com. through the at&t network, edge-to-edge intelligence gives you the power to see every corner of your growing business. from finding out what's selling best... to managing your fleet... to collaborating remotely with your teams. giving you a nice big edge over your competition. that's the power of edge-to-edge intelligence. that could allow hackers devices into your home.ys and like all doors, they're safer when locked. that's why you need xfinity xfi. with the xfi gateway, devices connected to your homes wifi are protected. wh

biogen said patients in a high dose of aducanumab had 23% less cognitive decline after 18 months than able to do household chores. abnormal amyloid, then it will show up as red... aducanumab is designed to clear amyloid, an abnormal protein which ravages the brain, so could it be the wonder drug scientists have spent decades searching for? i have to be cautious here because of what's happened in the past. so, i hope we have the first drug that's going to slow alzheimer's, but i have to see more to be fair to my patients and the people that have got hope. but if we do, it would be enormous? yeah, it would be the biggest thing that's happened in alzheimer's — ever. and medical regulators will be poring over all of biogen's as yet unpublished trial data before they decide whether to grant it a licence. they'll be very cautious indeed. it's relatively immature data. they'll be looking incredibly closely at that and normally what they would want to see is a second study, to confirm those results. if aducanumab passes all its regulatory hurdles, it's still likely to be another two—three yea

biogen move. day after his stocks soared on that nuancemeannouncement thd seek experimental -- for its alzheimer's drug still, plenty of skeptics about all of this. here's what the ceo had to say. >> it was a thorough engagement and the evidence came over time. we collected tremendous and -- and complex set of data, including bio markers and imaging. and the fda dedicated a lot of time to engage with us so that we come to the second meeting. as a ceo, i'm reasonably confident that this can lead to the market approval. >> so talk us through some of the -- i mean, the controversy is a little bit around -- you pointed out yesterday the analyst community not as excited as the investing community necessarily. they're like we don't know if this path of treatment, if we want to resurrecis and go down this route again. >> yeah. so there is a lot of skepticism around alzheimer's drugs just because they've been so difficult to develop and this approach toward removing these plaques in the brain has never wo

biogen spent more money than anybody else.cacy was not there in trials, you shop shares plunge 25%. this is a stock that has been bound in this range. they had nothing in the pipeline. they are dependent on those multiple sclerosis drugs which are aging out. alzheimer's was the next future. the fact that they're able to turn this around, who knows what is in the data. they are willing to go back and get this approved. if that is the case, you're talking about a multibillion-dollar stream of revenue for the company and that is why you are seeing shares up this morning. alix: huge down. romaine: and the gap up we are getting today was recouping what we have lost going back to march 21. alix: it is time for bottom line. we'll take a look at companies worth watching. the first is wework. adam neumann will be stepping down from the company's board. joining us is sonali basak. stepping down but getting payouts from softbank? about $1.7 million -- about $1.7 billion. this is basically an unwind of his stake in the company and his con

biogen's ceo will be on squawk tomorrow >>> ver text up nearly 4% another great development. we'll talk about the impact on the company and the industry from that one ahead. >>> meantime a news alert on facebook >>> kelly, mark zuckerberg will tell lawmakers tomorrow on capitol hill that facebook isn't the ideal mess enger for lib ra. the written statement that the house financial services committee released ahead of that hearing tomorrow, zuckerberg will continue to defend their push for lib ra. saying he believes that facebook should be putting power at the hands of people. also, in this seven-page statement, zuckerberg said he doesn't believe that libra will compete with solvent currencies. he said that monetary is the province of central banks and not of libra now, zuckerberg will be testifying tomorrow in the hearing tomorrow that's just behind me. though the hearing is focused on libra and housing. you can expect he'll be questioned on everything from election interference to this expanded ooent trust investigation. he'll be in the hot seat for quite a while. >> we'll t

we'll talk about it later. >> thank you biogen or some of the other pharmaceuticals?> sign on the xpi definitive track how it's going to run epilepsy drug. generics are done not just by generic company but big names as well generic makers have their margins. have you bipartisan support -- not that we'll see legislation of any sort in this administration or even the next. we've got bipartisan support -- >> why not why don't you think so >> take a look at zuckerberg hearings, huge question mark do you think those people can get anything done, anywhere? it's doubtful. i'm staying away from it there are other places to find value in the market. i bought fedex, one bob talked about, when it got crushed that's where i would rather go real fundamentals that don't have regulatory overhangs. that's where i prefer to be. >> got t 40 minutes before the close. dow is back down on session lows 32 points right now. after the break, analysts are weighing in as stocks take a leg lower despite upbeat third quarter results. we'll get the word on the street on that name. >>> steeking of

biogen said patients on a high dose of aducanumab had 23% less cognitive decline after 18 months than red... aducanumab is designed to clear amyloid, an abnormal protein which ravages the brain, so could it be the wonder drug scientists have spent decades searching for? i have to be cautious here because of what's happened in the past. so, i hope we have the first drug that's going to slow alzheimer's, but i have to see more to be fair to my patients and the people that have got hope. but if we do, it would be enormous? yeah, it would be the biggest thing that's happened in alzheimer's, ever. and medical regulators will be poring over all of biogen's as—yet unpublished trial data before they decide whether to grant it a licence. they'll be very cautious indeed. it's relatively immature data. they'll be looking incredibly closely at that and normally what they would want to see is a second study, to confirm those results. if aducanumab passes all its regulatory hurdles, it's still likely to be another two to three years before it comes on the market here in the uk. it will undoubtedly

if approved, this would be a big deal for biogen and the alzheimer's community.the new data despite the major move higher in the stock yesterday, guys. >> stay with us, you are going to help us out here with this. joining us now first on cnbc, the biogen ceo there is a lot of skepticism i don't know in the analyst community, sometimes skepticism is good when they don't understand they are not buying into new results. >> thank you for having me what it demonstrates again is the road to breakthrough innovation is full of twists and turn it is a process. the persistence and passion and specialization of the company in that space demonstrates that it leads tosuccess. designed to the data seen in the patiences, you are saying it actually removes the plaques you are convinced beta analoid is the key >> more than ever. we are seeing this antibody who is binding to the right part of the beta is able to erode and eliminate the plaque leading to the benefits we see in terms of cogniton we are seeing effects in terms of memory and more >> not in all the studies you did thou

biogen says it will soon ask us regulators for approval.rugs only help with the symptoms of alzheimers — so if given the go ahead it will be a major breakthrough in the treatment of the disease. here's our medical correspondent fergus walsh. this is an extraordinary turnaround. backin this is an extraordinary turnaround. back in march, biojen suddenly without warning halted clinical trials involving more than 3000 patients worldwide, some of them here in the uk saying this drug does not work. —— biogen. now it is analysing more data and set for patients with early alzheimer's, on the higher dosage, it doesn't bring significant clinical benefits, slowing their cognitive and allowing them to preserve more of their memory language skills and ability to do things like wash and dress themselves. we have to be cautious, scientists have not seen all of the day together. but if it does work, it would be the first drug to slow alzheimer's and it would be a massive medical breakthrough. a blockbuster drug, and it would be transformative for this fiel

biogen says it will soon ask us regulators for approval.e symptoms of alzheimer's — so if given the go—ahead, it will be a major breakthrough in the treatment of the disease. here's our medical correspondent fergus walsh. this is an extraordinary turnaround for this drug which is called aducanumab. back in march, biogen suddenly without warning, halted clinical trials involving more than 3,000 patients worldwide, some of them in the uk, saying this drug does not work. well, now it's analysed more data and it's said for patients with early alzheimer's, on the higher doses, it does bring significant clinical benefits, slowing their cognitive decline and allowing them to preserve more of their memory, language skills and ability to do things like wash and dress themselves. we've got to be cautious because scientists haven't seen all of the data yet. but if it does work, it would be the first drug to slow alzheimer's and it would be a massive medical breakthrough. it would be a blockbuster drug, and it would be transformative for this field of

. >> thank you >>> billi >>> biogen is the stock today. remember back in march the stock plummeted when they said they were halting the trial for this very same drug it plummeted 25% we have new details here >> this almost never happens and it couldn't have happened in disease more plagued by setback than alzheimer's biogen plans to file for approval next year of its kpe t experimental drugs after a new analysis shows the late trial succeeded. earlier their stopped the drug on analysis that predicted the trials wouldn't work they made decisions to stop the trials in march. now the company says subsequent data on more patients. more than 2,000 show the drug appear to slow declines associated with alzheimer's. that da ta on patients and they had a higher dose in later analysis given how many people have alzheimer's disease, almost 6 million americans, it would be major advance and major boom for business >> is this also big news for the same sort of class of drugs that attack the plaque in the brain which is at the root of alzheimer's? >> ye

the us drug company biogen says it's seeking approval for a drug which appears to slow the disease. and... should a 30—something launch a dating app for the over—50s? we'll catch up with the entrepreneur behind it. a marriage of planning expertise with a multicultural background. we'll get the inside track on how to compete in the crowded wedding planning field. the founder of la fete joins us live. and we want to know is a dating out the best way to meet a potential partner? how did you meet yours? and if you are single, do you use dating apps? let us know — just use the hashtag bbcworklife. hello and a warm welcome to worklife. many have you have been in touch already about how you met your partner, it is great to see your stories and keep them coming, we will mention a few later. we start in the uk, where developments in the house of commons yesterday have prolonged the uncertainty over brexit. mps initially backed prime minister boris johnson's withdrawal agreement to take britain out of the eu in principle. it's the first time the commons has approved a brexit deal. but mps the

biogen is run two studies.g on the two studies, they weren't showing great effects. they showed side-effects. so they pulled it. charles: the efficacy part of the trials? >> now they went for fda approval. there apparently was some data from smaller studies in substantive patients with the higher dose it was showing some cognitive improvement in the world of alzheimer's. we don't have peer reviewed studies. or alzheimer especially i've reviewed this. all they're doing is seeking approval from the fda. it doesn't necessarily mean it is going to work. charles: by the same token it is hard to imagine they would have made this announcement or this decision if they weren't, didn't have some level, certainly much higher level of confidence than they had before. it wasn't just with them. i think everyone was hoping this idea that it was the plaque on the brain and there was a way to fix that. because it is not just six million people, doc. it is their families. it is insidious. one of the worst things that can happen

biogen said patients on a high dose of aducanumab had 23% less cognitive decline after 18 months thanchores. abnormal amyloid, then it will show up as red... aducanumab is designed to clear amyloid, an abnormal protein which ravages the brain, so could it be the wonder drug scientists have spent decades searching for? i have to be cautious here because of what's happened in the past. so, i hope we have the first drug that's going to slow alzheimer's, but i have to see more to be fair to my patients and the people that have got hope. but if we do, it would be enormous? yeah, it would be the biggest thing that's happened in alzheimer's, ever. and medical regulators will be poring over all of biogen‘s as—yet unpublished trial data before they decide whether to grant it a licence. they'll be very cautious indeed. it's relatively immature data. they'll be looking incredibly closely at that and normally what they would want to see is a second study, to confirm those results. if aducanumab passes all its regulatory hurdles, it's still likely to be another two to three years before it comes o

shares of biogen searching this morning after consulting with the fda.proval for new treatment for alzheimer's disease. guy: ubs wealth management assets reaching a record high. the ceo struck an up tone after the banks results. he spoke in zurich. >> i would try to do something else with my money before i buy negative rates bond. definitely the real issue is to say how to address that while staying diversified. myselfy have a hard time to reconcile this concept. of 19ect in the region million a year cost savings and most importantly i think it's going to give us an opportunity to refocus our activities. still very challenging market conditions. i'm glad we were able to bring a solid performance in this difficult context. performance just doesn't get it done. what are they going to do about the share price at the union bank of switzerland? right now our chief financial correspondent. we will get to the success of that effort in a moment. i want to show a chart which goes to wonderful reporting today on u.s. bancorp. this is a major bank and they've gone

hold back in march that is because the medication was deemed not promising enough at the time but biogenluded more patients showed much better results, according to the company the trial suggested the drug can offer significant benefits to alzheimer's patients, including improvements in memory orientation and language biogen which developed the drug with japanese partner yay sah says it will file for an fda approval earlier next year, currently there is no real drug to cure alzheimer's. >>americans in most states will see their health insurance premiums drop next year that is if they buy it on and obamacare exchange affordable care act premiums are dropping an average of 4% in 38 states including california and 20 more insurers are also joining in on the program. it marks the second year of lower rates in 6 states are seeing double digit declines many health care experts argue that obamacare is stronger because insurers have raised rates enough to make the exchange profitable. >>the fda is under mounting pressure to finalize its policy on flavored e cigarettes. the chairman of the house

there's new hope now that nearly 6 million americans who are living with alzheimer's drugmaker biogen will seek approval by the fda for aducanumab. the company said earlier this year that initial results for that drug were ineffective and halted the studies, but shares of biogen soaring on the news that they are rethinking this. it is up 27% so far this week. here with us now is fox news medical correspondent dr. marc siegel. in the past it was considered ineffective. now effective. what's the difference? >> here's what's going on, david, there's a protein that clogs the brain in alzheimer's called beta amyloid it makes plaques in the brain. this drug targets that protein. it is targeted therapy. if it targets the protein, by the time it's already built up in the brain, it is already too late. the question is can it be used early enough? we're having more and more diagnostic tests, pet scans and blood tests that tell us that on the road to alzheimer's, before you even vishave it, there's a place for this drug, early on. the reason now that biogen is getting another look at it and why

the company, biogen, says it will soon seek regulatory approvalfor the drug in the us.. this seems like a remarkable breakthrough. an extraordinary turnaround for the drug, because in march biogen without warning courted clinical trials involving more than 3000 patients worldwide, some with them in the uk, saying this drug does not work. but now it has analysed more data and it is said four patients with early alzheimer's, on the high dosage, it does bring significant clinical benefits, slowing their cognitive decline and allowing them to preserve more of their memory, language skills and ability to do things like wash and dress themselves. we have got to be cautious because scientists have not seen cautious because scientists have not seen all of the data yet, but if it does work it would be the first drug to slow alzheimer's and it would be a massive medical breakthrough, it would be a blockbuster drug and it would be a blockbuster drug and it would be a blockbuster drug and it would be transformative for this field of research. alzheimer's is the most common form of

we saw a nearly 40% rally in biogen. stage trials of this treatment as the analysis they looked at revealed the trials had little hope of succeeding. but now they have new analysis that showed one of the trials actually met the main goal, the other did not, and now this fresh analysis of that data has given them hope and has given caregivers, patients, family members hope across the world. so millions could be looking at quite a remarkable breakthrough when it comes to alzheimer's. >> so many lives can be changed if this drug can actually deliver. thank you, juliana. . coming up, a look at "axios" one big thing. >> democratic congressman eric swalwell joins the conversation with his take on ambassador bill taylor's testimony in the impeachment inquiry, "morning joe," everyone just moments away. and be open with your doctor about anything you feel - physically and emotionally. but now cigna has a plan that can help everyone see stress differently. just find a period of time to unwind. a location to de-stress. an activity

pero ahora las acciones de biogen se dispararon hasta en un 37% gracias al Éxito de la terapia con estelatinos de los angeles adoptÓ lamÁs estrictas medidas para prevenir los daÑos que provoca el uso del cigarrillo electrÓnico o vapping. el gobernador de california pide invea las compaÑÍas petroleras por los altos precios de la gasolina en ese estado. jorge: en breve, dos equipos repletos de jugadores espaÑoles disputan desde hoy la ♪ ♪ patricia: cuando hoy salgan al terreno a disputarse la serie mundial de bÉisbol, casi la mitad de los jugadores de houston y de washington serÁn hispanas. la sede del primer partido es houston, cuyo equipo se coronÓ campeón de la liga americana. tambiÉn se juega en washington donde los nacionales de washington se impusieron en la liga nacional. la serie entera tendrÁ mucho sabor latino. >> la fanaticada pone sus ojos en texas donde disputen el primer encuentro por la serie mundial de la liga del bÉisbol profesional. alrededor del estadio se congrega miles de fanÁticos, entre ellos el seÑor josÉ martÍnez. >> voy a entrar al juego. houston ha tenido desde

shares of biogen soared almost 30% on the news. nike is getting new leadership.stepping aside as chief executive. he will be replaced by john donohue. currently he's the chairman of pay pal. parker will be the executive chairman. this comes hours after another sports brand ceo stepped down, kevin plank of underarmor. plank's wealth jumped by $89 million as shares in under armour rose after the announcement. and chipotle is running out of steak. it's specialty dish has been so popular it will probably be done by december. the steak contributing to chipotle's strong third quarter. sales rising 11%, revenue july ping nearly 15% -- jumping nearly 15%. they also announced the addition of drive-through lanes to new restaurants. that could delay the opening of some. lauren: i better get the steak while i can. thank you. cheryl: let's take a look at your money this morning. it's going to be a big day for earnings. it's all about one name, folks, today. that is boeing, before the bell. right now you've got a little bit of pressure on the markets, dow down 20, s&p down 1 a

i think one by one they might all be believers because biogen resumed this work at beheftd of the fdaext year's earnings. that's insane. this is a $54 billion company that could be worth double last night amgen reported a better quarter that didn't require management to cut their forecast. amen i'm calling that a win with these guys amgen started to win back major market share in the migraine business their key franchise amovig had been the market leader until eli lilly started making major inroads with the drug distributors and drug stores amgen hasn't done such a good job. last year i want on the phone with mckesson for hours and even when i got it they wouldn't send it for where i want td to go they were horrendous now that amgen's getting it into drugstores on top of that they're just scratching the surface with the sore yachtic arthritis drug they bought from celgene because celgene had to sell it according to the government to merge with bristol-myers. speaking of bristol-myers it had a superb quarter too i expect the celgene deal will make them a fortune once it closes in decem

biogen, the stock is surging this morning. >> i did it's up 30%. >> up 30%.t do you do it's had a tough year though. >> it has. biogen over the last couple of years hasn't really done as great as some of the others. i think the question is let's see exactly where they are i have not read the release. up 30%. >> alzheimer's drug. alzheimer's drug that they had said was -- the early results they thought were bad. it was sort of shelved for a period now it's come back they've re-looked at the numbers, there were additional studies. >> analysis. >> there's some hope. >> that's the thing when you invest >> look at that, up 32% right now. pretty remarkable. you can see what that stock looked like all year >> it's hard to measure progress though 23% reduction in the clinical, what's measured as a clinical decline in your abilities versus a placebo. so that's a statistically significant movement nothing for alzheimer's. >> right it's an area where there's really not a lot of competition. if they've got something that's new, i think they'll get credit for it. >> okay.

not bad for biogen. let us now go to london and the debate over brexit. it is now raging. just minutes after parliament voted down prime minister boris from the european union on october 31st. they said no. johnson says it was joyful that the house actually accepted his deal in the first vote today, but he's disappointed in yet another what he called delay. what does this mean and could it be why, ashley, our market has really clipped some of the gains here? you're there. you are watching the events in parliament. you are in london. tell us how you perceive this. ashley: well, i think this was expected to be honest with you, liz. the initial reading of the bill that he introduced, all the nuts and bolts of his agreement with the eu was approved. all that meant was yes we will look at it. the second vote, the one where the government only gave parliament three days to go through the pages of the text, well, it was not unexpected that he was not going to be able to push that through because boris johnson wants it to fast track. he wanted to get this thing through parliament,

the second worst performance of the year biogen, pfizer, cigna weighing on the space, down double digits the sector has been caught in the crosshairs of late as the 2020 election draws closer our truck master carter worth has a prognosis. she on the plasma. >> we're not really at the plasma not yet. are you going to go there? >> i'm waiting for per mention. >> permission granted. you are banished from the desk >> thank you >> so, you know, this has obvious been a dud, in many ways, it was a year of risd hig market, reit staples, winning, healthcare is that other area that's both defensive but is offensive. at this point it's a head you win, tails you win, let's talk about it so since data is available back in 1989, this is a chart showing healthcare's weight as a percentage of the s&p. and it has been higher, as high as 16.5. obviously, it's been lower right now we're at 13.5% the average is about 12 and my thinking here is that not necessarily dependent on this, but that there is surprise potential in healthcare. let's look at a few charts so this is well, just to show you, this is how

earlier this year biogen scrapped research saying the drug didn't work.ny now says new analysis suggests it was effective in higher doses. some experts are skeptical for several reasons including the fact that the company hasn't released the data. >>> e-cigarette company juul is facing a lawsuit allege is the company marketed its products to minors and young adults. here is abc's linsey davis. >> i had to learn how to walk again, basically. i couldn't really walk. >> reporter: in a new lawsuit, 21-year-old conner evans alleges his 2 1/2 weeks in a pennsylvania hospital are directly linked to his year-long vaping of the popular e-cigarette juul. >> my lungs were filled up to 80% of the capacity filled with fluid. >> reporter: evans is suing the company claiming it failed to warn him about the dangers. the once-healthy high school hockey captain was admitted to the hospital in may having great difficulty breathing, later placed in a medically induced coma for eight days. >> you're sitting in a bed, your parents are just looking at you, your family, you know

he sharesel a fraction to 34.12.biogen upgraded to outpro market from market fireman.y say the experimental alsz heimers drug that itlans to submit for approval. the price t $370 shares up a fracture to. 299. well facebook users don't appear to be phased by the political pressure facing the social media company. it reported better than expected earnings and revenue and saw user base grow. that sent the stock higher inl initia after hours trading. julia boorstin has the details.r >> rr: the key takewa a from phone number earnings the social giant fing on all cylinders. beating expectations across the board. drawin advertisers and using despite the regulatory concerns about the compa and investment in protecting the platform. the key metric of facebook success, average revue peruser. the number grew to 7.26. this that's more than 20 cents better than analyst consensus expectations and. and perhaps most notify notable the nototy most valuable user i ba u.s. and canada. stagnating over the last two years. in t third quarter facebook grew daily active usenersu. the and cana

so biogen earlier this year looked at this data and went no, it does not work.d looked at the patients were getting the very very highest doses and their benefit in terms of memory, language ability and day to day tasks like getting dressed in the morning, so the question now is what does it really mean? so scientists want to see the data and much greater levels of detail than they are able to at the moment and only then will they be saying if this is a turning point in dementia or not. this is 0utside source live from the bbc newsroom. 0ur lead story is... britain's prime minister, borisjohnson, has halted crucial legislation on brexit, after mps rejected his government's short timetable for parliament to consider it. let's quickly look at some of the new stories from bbc world service. the canadian prime ministerjustin trudeau has been returned to power. but he'll be forced to work with other parties after losing more than twenty seats — adn with them his majority. it's expected his new minority government will seek support from the smaller new democrat party

this year up just 6% and the second worst performing sector of the year behind manager names like biogen. centene. the space downhill double digits in the cross hairs of late as the 2020 presidential election draws closer but our chart master carter weather has a positive prognosis at the space and he is at the plasma he is not yet at the plasma. >> not yet. >> are you going there. >> i'm waiting for permission. >> you have my permission. banished from the desk. >> thank you this has obviously been a dud. what's interesting is it was a year of risk off in highly defensive areas of the mechanic, specifically utilities, reits, staples winning. health care is the other area at a that's defensive but offensive. in a which i think at this point it's a hedge you win, tails you win. let's talk about it. so since data is available back in 1989, this is a clarity showing health care's weight as a personal of -- percentage of s&p it's been higher, 16.5 and obviously it's been lower. are the right now at 13.5% the average is about 12 appear and my thinking here is that not necessarily depend on thi

biogen says it will soon ask us regulators for approval. only help with the symptoms of alzheimers — so if given the go ahead it will be a major breakthrough in the treatment of the disease. the man whose extradition case sparked the past six months of protests in hong kong has agreed to return to taiwan voluntarily, to face prosecution for murder. it's alleged chan tong—kai murdered his pregnant girlfriend during a holiday in taiwan last year. he fled back to hong kong, which has no extradition deal with taiwan, and his case was cited when the government proposed amending the law. the former top us diplomat in ukraine has testified that he was told president trump had made the release of military aid to ukraine contingent on a public declaration from kyiv that it would conduct an investigation into the former democratic vice—president, joe biden. william taylor's evidence to congressional committees leading an impeachment inquiry was met with gasps in the closed—door hearing. donald trump has denied using a threat to withdraw military aid

the company, biogen, says it will soon seek regulatory approvalfor the drug in the us.s an extraordinary turnaround for the drug. backin back in march they halted clinical trials involving more than 3000 patients worldwide, some in the uk saying this drug does not work. now it has analysed more data and it says for patients with early alzheimer's on the higher doses, it brings significant clinical benefits, slowing their cognitive decline and allowing them to preserve more of their memory, language skills and ability to do things like wash and dress themselves. we have to be cautious because scientists haven't seen all of the date yet, but if it does work, it would be the first drug to slow alzheimer's and it would be a massive medical breakthrough, it would be a blockbuster drug and it would be a blockbuster drug and it would be a blockbuster drug and it would be transformative for this field of research. alzheimer's is the most common form of dementia and dementia affect 850,000 people just here in the uk. fergus walsh there. electric cars could be given green number

other news, continuing to surge up over 8% it had hit the daily limit high after confirming that biogen would produce plans for approval for drug trooemt and stocks as well back to you. >> thank you for that color live from tokyo >> coming up, we'll hear as the drug maker warns strong momentum in china can't continue more after the break >>> british authorities say all 39 people found dead in a refrigerated truck were chinese citizens investigators are looking into one of the most dangerous cases of human smuggling >> people are leaving flowers where they were found. police continue to search the site for fingerprints and other evidence it is believed the truck crossed in on a ferry from a port in belgium. they say the trailer arrived at their north sea port and left for england a short time later it is not clear if the 39 victims were put into that container, possibly sealed and refrigerated the 25-year-old truck driver is being held on suspicion of murder but has not been charged. where did that truck originate, when and where were those victims put inside and where were they headed >

the company, biogen, says it will soon seek regulatory approvalfor the drug in the us.s gallagher is here. this is the holy grail of alzheimer's research but there is a long way to go, surely. exactly. there have been many false dawns before, but there is genuine excitement because what you have to remember is there is no drug that can slow the pace of any dementia, so if this one is capable of doing it in alzheimer's, that would genuinely be one of the biggest moments in modern medical research, however the question is, are we there yet. we are not entirely sure we have the answer, so biogn looks at the date and said it didn't work, but now it looked in more detail and it's looked at the patients who are getting the highest doses and is there a benefit in terms of memory, language ability and day to day tasks like getting dressed in the morning. so the question now is, what does it really mean? scientist wa nt to what does it really mean? scientist want to see the data in much greater levels of detail than they are able to at the moment and only then will they say if t

biogen regained all of the lost market value and more.ket, it is a huge milestone in history of alzheimer's, for which there is no cure. we can expect these two pharmaceutical companies to keep surging. haidi: what is the timeline we are looking at? aa approval for any drug is multi-process. rachel: from what we understand, the drug is close to the finish line. the companies already talk to the fda when they really looked at data and they were encouraged by the fda to come back to the table. we know that the fda will go to a panel of outside experts and listen to their recommendation but the drug is quite close to coming onto the market. it is not years away, it is months away. shery: thank you so much for that. turn to boeing, the head of the boeing unit in charge of the troubled 737 max 8 jetline has stepped down after less than three years in the job, the latest sign that the crisis and boeing is deepening and likely to over shower -- overshadow wednesday earnings. despite the reshuffle in management, we have seen boeing rallying. what

surgings of biogen today, up 30% on renewed hopes of an alzheimer's treatment a lot thought were deadmaker will ask approval of the experimental therapy after a new analysis of clinical trials. take me back to march, the stock sold off by 30% when it was apparently data that showed the drug didn't meet some efficacy requirement and was pulled. >> sure, what happened in march was the trial had an analysis. you don't necessarily know when they are, but when the company did the analysis on the 1700 patients that had reached the required status in the trial, they said it doesn't seem it is going to work, so what happened today is they said we have had more patience, 300 more patients, so around 2000 and they say now we think the trial works. ther are key nuances in e. >> a change in leadership, but not a strategy at under armour. 2020, the ceo of is stepping down at the company he started in 1995 and will stay on as executive chairman. under armour posh president and coo will step in as the new ceo january 1. >> this is my decision in concert with the board of patrick joinede to a half ye

biogen leading the charge. a lot of the other stocks in that sector also rising in sympathy.speculation about what the next big drug could be and whether other companies be along for the ride. the aerospace sector, these are a lot of the suppliers, bowing up a couple of percentage points. that is dragging some of the suppliers up. on the bottom, some of the software companies. we had cadence out with earnings last night. that is the big software design companies. there guidance disappointed earnings. that is dragging down some of the software companies. keep in mind the software companies have been a big source of keeping this rally going over the last few weeks, since the end of the summer. if we get a little but of softness, that could spell trouble for the market. something to keep an eye on. tomorrow with out numbers. the earnings call starts at 10:30 eastern. that will be a must listen call. let's get back to the bank earnings season story. we have kicked it off in europe. ubs out with numbers earlier. it's wealth management unit added 50.7 billion new dollars. the ceo b

biogen will revive an alzheimer's drug that it had shelved. the stock is going to be up, what, 36%, over 80 bucks up right there at the opening bell. a chinese company reportedly considering a bid for the vitamin retailer gnc. that stock is up close to 20%. the toy maker, hasbro, says okay, tariffs on toys made in china did hurt them. the stock is down 15%. dow component procter & gamble raised guidance for the year and reported strong growth in its beauty and health businesses. that's good enough for a 4% gain for a giant company. procter & gamble. >>> better profit at harley davidson. international sales of its bikes up nicely. that's international sales. 6% gain for the stock as of right now. then we have, let's get back to it, the dow component mcdonald's. that is going to be a drag on the dow, at least at the opening bell today. lauren simonetti is here. lauren, you know how i feel about this. i don't want to talk about expectations. i think the report shows mcdonald's keeping its place as the number one fast food retailer on the planet.

. >> we'll see how long he keeps this >>> still to come, shares of biogen seeing a huge pop in today's session, up around 30% we'll tell you what's behind that move. >>> and as we head to break, here's a check on bonds. u.s. treasury yields a bit lower today. but still higher so far in the month of october with the ten-year yield hovering just a little less than 1.8, 1.78%. in the human brain, billions of neurons play in harmony. for people with parkinson's, some neurons change their tune, causing uncontrollable tremors. now, abbott technology can target those exact neurons. restoring control and harmony, once thought to belost forever. the most personal technology is technology with the power to change your life. >>> welcome back we've got 28 minutes left to trade and the dow is higher by about 50 points. s&p is flat, nasdaq is lower the key things driving the action, upbeat earnings reports are pushing earnings broadly higher, but two specific disappointing earnings reports from dow companies are keeping the rally limited. although the dow is leading. and new details on an anti-trust